Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Kristina Stoeppler-Biege"'
Autor:
Howland E. Crosswell, Erin B Hill, Kristina Stoeppler-Biege, Lara H Widener, Dionne Pringle, Robert D. Siegel, Theresa M Standifer, Terra F Spann, Michael Borron, Karen K Hancock, Richard Slough
Publikováno v:
Journal of Oncology Practice. 15:e628-e635
PURPOSE: The cost of cancer care is escalating dramatically, in part because of the rising expense of systemic cancer therapy. This creates financial dilemmas for patients and insurers and potential economic disruption for institutions attempting to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44073debe5008b0bbbdee965e8323bc4
https://doi.org/10.1200/jop.19.00016
https://doi.org/10.1200/jop.19.00016
Autor:
Nicole Vickery, Kaitlin Bomar, Howland E. Crosswell, Kristina Stoeppler-Biege, Robert D. Siegel, Terra Spann
Publikováno v:
Journal of the National Comprehensive Cancer Network : JNCCN. 15(9)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::739826e93d6b27022a6d07891fb8bafc
https://pubmed.ncbi.nlm.nih.gov/28874601
https://pubmed.ncbi.nlm.nih.gov/28874601
Autor:
Kristina Stoeppler-Biege, Dionne Pringle, Bonnie Helms, Theresa M Standifer, Michael Borron, Robert D. Siegel, Richard Slough, Terra Spann
Publikováno v:
Journal of Clinical Oncology. 36:121-121
121 Background: The cost of oncology drugs has escalated rapidly while rollbacks in health care coverage and the emergence of high deductible and limited policies have made these drugs unaffordable for many. Many pharmaceutical companies offer drug r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0e878161a4f6fe55ebd79992535e380f
https://doi.org/10.1200/jco.2018.36.30_suppl.121
https://doi.org/10.1200/jco.2018.36.30_suppl.121
Autor:
Dionne Pringle, Kristina Stoeppler-Biege, Bonnie Helms, Theresa Sandifer, Michael Borron, Richard Slough, Robert D. Siegel, Terra Spann
Publikováno v:
Journal of Clinical Oncology. 36:e18642-e18642
e18642Background: The cost of oncology drugs has escalated rapidly while rollbacks in health care coverage and the emergence of high deductible and limited policies have made these drugs unaffordab...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::43d5b1fc5e5f943dc02d9d3213dafb36
https://doi.org/10.1200/jco.2018.36.15_suppl.e18642
https://doi.org/10.1200/jco.2018.36.15_suppl.e18642